Quick Answer
Q32 Bio Inc. reported Research And Development Expense of $19.16 million for the year ending 2025.
- Q32 Bio Inc. showed a decrease of -60.2% in Research And Development Expense from 2024 to 2025.
- This data is from Q32 Bio Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $2.80 million | Q2 2017: $4.06 million | Q3 2017: $4.95 million | Q1 2018: $8.00 million | Q2 2018: $10.29 million | Q3 2018: $13.39 million | Q1 2019: $20.54 million | Q2 2019: $22.83 million | Q3 2019: $25.69 million | Q1 2020: $29.31 million | Q2 2020: $27.47 million | Q3 2020: $20.42 million | Q1 2021: $21.76 million | Q2 2021: $23.70 million | Q3 2021: $23.99 million | Q1 2022: $24.27 million | Q2 2022: $21.08 million | Q3 2022: $25.85 million | Q1 2023: $7.91 million | Q2 2023: $8.02 million | Q3 2023: $7.46 million | Q1 2024: $9.84 million | Q2 2024: $13.41 million | Q3 2024: $14.35 million | Q1 2025: $7.12 million | Q2 2025: $5.16 million | Q3 2025: $3.56 million.
- Over the full 9 years of available data (2017 to 2025), Q32 Bio Inc.'s Research And Development Expense has declined by 10.4%.
- Historical annual values: Fiscal year 2025: $19.16 million | Fiscal year 2024: $48.14 million | Fiscal year 2023: $31.73 million | Fiscal year 2022: $98.35 million | Fiscal year 2021: $93.09 million | Fiscal year 2020: $100.39 million | Fiscal year 2019: $89.40 million | Fiscal year 2018: $47.95 million | Fiscal year 2017: $21.38 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: